Bendandi Maurizio
Department of Hematology and Cell Therapy Area, University Clinic of Navarre - Center for Applied Medical Research, Avda. Pio XII, 36 31008 Pamplona (Navarre), Spain.
Expert Rev Vaccines. 2004 Apr;3(2):163-70. doi: 10.1586/14760584.3.2.163.
Twelve years after the first formal demonstration that it is possible to vaccinate a cancer patient against an antigen derived from his/her own tumor, idiotype vaccines are now well into Phase III clinical trials for the treatment of follicular lymphoma. Meanwhile, their potential has also begun to be explored in other non-Hodgkin's lymphoma settings, such as that of mantle cell lymphoma. Another well known field of potential application for idiotype vaccines is that of multiple myeloma. However, the currently available results, even with the advent of dendritic cells, seem to be less promising than those obtained in lymphoma, to such an extent that idiotype vaccines are currently tested in multiple myeloma patients in the context of more aggressive therapeutic strategies.
在首次正式证明可以为癌症患者接种针对其自身肿瘤衍生抗原的疫苗12年后，独特型疫苗目前已深入到治疗滤泡性淋巴瘤的III期临床试验阶段。与此同时，它们的潜力也已开始在其他非霍奇金淋巴瘤环境中得到探索，如套细胞淋巴瘤。独特型疫苗另一个众所周知的潜在应用领域是多发性骨髓瘤。然而，即使随着树突状细胞的出现，目前可得的结果似乎也不如在淋巴瘤中获得的结果那么有前景，以至于目前独特型疫苗在多发性骨髓瘤患者中是在更积极的治疗策略背景下进行测试的。
